Anhui Fuyang Second People's Hospital
阜阳市第二人民医院
China
1 November 2019 - 31 October 2020
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for Anhui Fuyang Second People's Hospital published between 1 November 2019 - 31 October 2020 which are tracked by the Nature Index.
Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
| Count | Share |
|---|---|
| 2 | 0.34 |
Outputs by subject (Share)
| Subject | Count | Share | |
|---|---|---|---|
| Life Sciences | 2 | 0.34 | |
Top articles by Altmetric score in current window
Effective treatment of severe COVID-19 patients with tocilizumab.
Proceedings of the National Academy of Sciences of the United States of America
2020-04-29
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19
Nature Medicine
2020-05-19
1 November 2019 - 31 October 2020
International vs. domestic collaboration by Share
- 66.67% Domestic
- 33.33% International
Note: Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators by Share (8 total)
- Anhui Fuyang Second People's Hospital, China
- Domestic institution
-
University of Science and Technology of China (USTC), China
(1)
-
Sun Yat-sen University (SYSU), China
(0.14)
-
Bengbu Medical College, China
(0.07)
-
Bozhou Bone Trauma Hospital, China
(0.07)
-
Nanxishan Hospital, China
(0.07)
-
Sichuan University (SCU), China
(0.07)
-
Wuhan University (WHU), China
(0.07)
-
Zhejiang University (ZJU), China
(0.07)
Top 10 international collaborators by Share (4 total)
- Anhui Fuyang Second People's Hospital, China
- Foreign institution
Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
